A new analytical method development and validation for the estimation of Midodrine HCl by UV and HPLC

Vijeta Dhote*1, Prabhat Jain2 and Vivek Jain1

1Nri Institute of Pharmacy, Bhopal, India
2Scan Research Laboratories, Bhopal, India

**ABSTRACT:** Two simple, accurate, sensitive and precise reverse phase-high performance liquid chromatographic and U.V. assay method for estimation of Midodrine hydrochloride (MD) was developed in tablet formulation. The chromatographic separation was performed on Thermo C18, (250 mm X 4.6 mm, 5 µm) column. The mobile phase consists of water: acetonitrile (30:70 v/v) pH adjust 3.5 with TEA was delivered at a flow rate of 1.0 ml/min and UV detection at 272 nm. The retention time of the drug was found to be 3.89 min. The developed method was found to be linear in a concentration range of 5-25µg/ml of the drug (r2= 0.999). The low value of % RSD indicates reproducibility of the methods. The low value of LOD and LOQ suggests the sensitivity of the method. Thus, this method can be used for routine analysis of Midodrine hydrochloride formulation and to check the stability of bulk samples.

**INTRODUCTION**

Every year many new drugs and newer drug combinations enter the pharmaceutical area. The analytical methods for these new and first timer drugs are mostly confined only to the manufacturing company. However, availability of multiple analytical methods for the same drug/drug combinations in their formulations is always advantageous.

Moreover, development of such methods helps in training the analysts for skillfully handling the sophisticated analytical instruments and the way for research approach. Reference literature and general survey reveals that similar work of development of UV and HPLC methods for new drugs and their combinations introduced in the market is continuously underway in many academic institutions. The present work is also planned on similar lines[1,2].

The non-availability of analytical methods till now for the concurrent analysis of single and multi-component formulations made it worthwhile to pursue the present research work. It was also planned to validate the developed methods as per ICH guidelines.

Hence, they offer wide area for research activity with relatively minimum chances of exactly repetitive work. The pharmaceutical dosage forms are widely present with multiple active components i.e. in combined dosage forms. This has opened new task for analyst for simultaneous estimation of Midodrine hydrochloride in marketed formulation.

Therefore, in proposed project, to attempt to develop New, simple, accurate, cost effective and precise method for analysis of drugs in marketed formulation and validate them[2-4].
METHODS

Characterization and identification of midodrine hydrochloride

Physiochemical characteristics

Description- Solid, off white powder.

Melting point- M.P. of the drug was 200-203°C found through Melting point apparatus.

Solubility- Solubility of Midodrine hydrochloride was established by I.P. method.

Chemicals and solvents

Table 1: Chemicals and Solvents Used

| S. No. | Chemicals          | Manufacturer                  |
|--------|--------------------|-------------------------------|
| 1.     | Midodrine HCl      | Working standard, API Grade   |
| 2.     | Methanol (AR Grade)| Solvent, Merck Ltd., India    |
| 3.     | Methanol (HPLC)    | Merck Ltd., India             |
| 4.     | Water (HPLC)       | Merck Ltd., India             |

Instruments & Equipment:

For UV method:

Absorbance measurements were made on UV-Visible spectrophotometer Lab India, model is 3000+ with 1cm quartz cell. For weighing, Wensar (max 1g, sensitive = 0.01 mg) balance was used.

For HPLC method:

The HPLC system consisted of a Waters isocratic System UV detector. Model no. 784. The software used was Data Ace, Separation was achieved on a reverse C18 (250mm×4.6mm 5µm).

Marketed formulation of Midodrine hydrochloride

Proamatine 5 mg tablets
Midodrine hydrochloride 5mg

Determination of solubility

Solubility of Midodrine hydrochloride was performed in different solvents.

Estimation of midodrine hydrochloride by spectrophotometry [6-11];

Area under curve method:

Determination of $\lambda_{max}$ of Drug

Standard solution (10µg/ml) of pure Midodrine hydrochloride was prepared. The pure drug solution was scanned on UV spectrophotometer, which showed maximum absorbance at 272.0 nm.

Experimental Procedure:

Preparation of Standard Stock Solution

10mg of Midodrine hydrochloride was weighed accurately and transferred to a 10ml volumetric flask, and the volume was adjusted to the mark with the diluent water, to give a stock solution of 1000ppm.

Preparation of Working Standard Solution

From stock solutions of Midodrine hydrochloride 1 ml was taken and diluted up to 10 ml. from this solution 0.5, 1.0, 1.5, 2.0 and 2.5 ml solutions were transferred to 10ml volumetric flasks and make up the volume up to 10 ml with water gives standard drug solution of 5, 10, 15, 20, 25 g/ml concentration.

Preparation of the calibration curves of the drug

The standard drug solutions were taken absorbance 3 times and the mean area of drug was calculated and plotted against the concentration of the drug. The regression equation was found out by using this curve. A typical spectrum and the calibration curve were obtained.

Preparation of analysis of tablet formulation

20 tablets were weighed and ground to a fine powder. Tablet powder equivalent to 10 mg Midodrine hydrochloride was weighed and transferred to a 10 ml volumetric flask and volume was made up to 10 ml with diluents (water) to obtain concentration of 1000µg/ml. Resultant solution was filtered through Whatmann filter paper.

1 ml of filtrate was taken in 10 ml volumetric flask and volume was made up to 10 ml with diluent to obtain concentration of 100µg/ml. Further 1.0 ml of this solution was taken and diluted up to 10 ml obtain final concentration of 10 µg/ml. Absorbance of the sample solutions at 272.0 nm was measured and from the absorbance values, the concentration of drugs in the sample solution was determined by using calibration curve Y=mx+c.

Validation

Linearity

Linearity of analytical procedure is its ability (within a given range) to obtain test, which are directly proportional to absorbance of analyte in the sample. The calibration plot was constructed after analysis of five different (from 5 to 25 g/ml) concentrations and area for each concentration were recorded three times, and mean absorbance was calculated.

The regression equation and correlation coefficient of curve and the standard curve of the drug is shown in figure.
Accuracy

Recovery studies were performed to validate the accuracy of developed method. To pre-analyzed sample solution, a definite concentration of standard drug (80%, 100%, and 120%) was added and then its recovery was analyzed.

Precision

(A) Repeatability

Standard dilutions were prepared, and three replicates of each dilution were analyzed in same day for repeatability and results were subjected to statistical analysis. Standard dilutions were prepared, and three replicates of each dilution were analyzed in different days and by different analysts. Statistical analysis was carried out.

(B) Intermediate Precision

(a) Day to Day

(b) Analyst to Analyst

The intermediate precision expresses with in laboratories variation: different days, different analysts, different equipment etc. The standard dilution was prepared, and three replicates of each dilution were analyzed by different analysts for all the developed methods.

LOD (Limit of Detection):

The Limit of Detection (LOD) is the smallest concentration of the analyte that gives the measurable response. LOD was calculated using the following formula.

\[ \text{LOD} = 3.3 \left( \frac{\sigma}{S} \right) \]

Where, \( S \) = slope of calibration curve, \( \sigma \) = standard deviation of the response.

6.6.5 LOQ (Limit of Quantitation):

The Limit of Quantification (LOQ) is the smallest concentration of the analyte, which gives a response that can be accurately quantified. LOQ was calculated using the following formula.

\[ \text{LOQ} = 10 \left( \frac{\sigma}{S} \right) \]

Where, \( S \) = slope of calibration curve, \( \sigma \) = standard deviation of the response.

Analytical method development by HPLC[11-14]:

Mobile Phase Selection:

Initially to estimate Midodrine hydrochloride number of mobile phase in different ratio were tried. Taking into consideration the system suitability parameter like RT, Tailing factor, No. of theoretical plates and HETP, the mobile phase found to be most suitable for analysis was Water (pH adjust 3.5 with TEA): Acetonitrile in the ratio of (20:80v/v). The mobile phase was filtered through 0.45µ filter paper to remove particulate matter and then degassed by sonication. Flow rate employed for analysis was 1.0 ml/min at the Amax 272nm.

Selection of wavelength:

100 mg of Midodrine hydrochloride was weighed accurately and transferred to a 100 ml volumetric flask, and the volume was adjusted to the mark with the mobile Water (pH adjust 3.5 with TEA): Acetonitrile in the ratio of (20:80v/v). From above solutions of 0.1 ml was transferred to 10 ml volumetric flasks and make up the volume up to mark. Resulting solution was scanned over UV range (200-400nm), maximum absorbance was found at Lambda max 272nm.

Selection of Separation Variable:

Standard drug solution of Midodrine hydrochloride was prepared in different mobile phase and chromatograph was recorded by using different column (5 and 10 µm) at different chromatographic condition like different flow rate and temperature. Considering the theoretical facts and after several trials separation variables were selected which were constant during whole experiment.

System Suitability Parameters:

Separation variables were set, and mobile phase was allowed to saturate the column at 1.00 ml/min. After complete saturation of column, three replicates of working standard of Midodrine hydrochloride 10µg/ml was injected separately. Peak report and column performance report were recorded for all chromatogram.

Preparation of Standard Stock Solution:

10mg of Midodrine hydrochloride was weighed accurately and transferred to separate 10ml volumetric flask, and the volume was adjusted to the mark with Acetonitrile to give a stock solution of 1000ppm.

Preparation of Working Standard Solution:

From stock solutions of Midodrine hydrochloride 1 ml was taken and diluted up to 10 ml. from this solution 0.5, 1.0, 1.5, 2.0, 2.5 ml solutions were transferred to 10ml volumetric flasks and make up the volume up to 100 ml with Acetonitrile, gives standard drug solution of 5, 10, 15, 20, 25 µg/ml concentration.

Preparation of the Calibration Curves of the Drug:

Standard drug solutions were injected 3 times and the mean peak area of drug was calculated and plotted against the concentration of the drug. The regression equation was found out by using this curve.

Analysis of tablet formulation[15-17]:

Assay of Tablet formulation:
20 tablets were weighed and ground to a fine powder. Tablet powder equivalent to 10 mg Midodrine hydrochloride was weighed and transferred to a 10 ml volumetric flask and volume was made up to 10 ml with Acetonitrile to obtain concentration of 1000µg/ml. Resultant solution was filtered through Whatmann filter paper. 1 ml of filtrate was taken in 10 ml volumetric flask and volume was made up to 10 ml with diluents (Acetonitrile) to obtain concentration of 100µg/ml. Further 1.0 ml of this solution was taken and diluted up to 10 ml obtain final concentration of 10 µg/ml.

The amounts of Midodrine hydrochloride in Tablet formulation was calculated by extrapolating the value of area from the calibration curve. Analysis procedure was repeated six times with Tablet formulation.

Validation:

Linearity:

Linearity of analytical procedure is its ability (within a given range) to obtain test, which are directly proportional to area of analyte in the sample. The calibration plot was contracted after analysis of five different (from 5 to 25 µg/ ml) concentrations and areas for each concentration were recorded three times, and mean area was calculated. The regression equation and correlation coefficient of curve are given, and the standard calibration curve of the drug is shown in fig. From the mean of AUC observed and respective concentration value, the response ratio (response factor) was found by dividing the AUC with respective concentration.

Accuracy:

Recovery studies were performed to validate the accuracy of developed method. To pre-analyzed sample solution, a definite concentration of standard drug (80%, 100%, and 120%) was added and then its recovery was analyzed.

Precision:

(A) Repeatability

Standard dilutions were prepared, and three replicates of each dilution were analyzed in same day for repeatability and results were subjected to statistical analysis. Standard dilutions were prepared, and three replicates of each dilution were analyzed in different days and by different analysts. Statistical analysis was carried out.

(B) Intermediate Precision

(a) Day to Day

(b) Analyst to Analyst

The intermediate precision expresses with in laboratories variation: different days, different analysts, different equipment etc. The standard dilution was prepared, and three replicates of each dilution were analyzed by different analysts for all the developed methods. The statistical analysis method was carried out and the data is presented.

Robustness:

As per ICH norms, small, but deliberate variations, by altering the pH and / or concentration of the mobile phase were made to check the method capacity to remain unaffected. The effect of change in pH of mobile phase, flow rate, mobile phase ratio on the retention time, theoretical plates, area under curve and percentage content of Midodrine hydrochloride was studied.

RESULTS AND DISCUSSION

Identification and characterization of drug

Results of melting point

Results: Melting point of midodrine hydrochloride found 200-203ºC

Result of FTIR of Midodrine hydrochloride

![FTIR Image](image)

Figure 1: FT-IR of Midodrine hydrochloride

Results of solubility study

Table 2: Solubility of Midodrine hydrochloride

| S. No. | Solvent            | Solubility     |
|--------|--------------------|----------------|
| 1      | Water              | Soluble        |
| 2      | 0.1 N HCl          | Soluble        |
| 3      | Methanol           | Freely Soluble |
| 4      | Ethanol            | Freely Soluble |
| 5      | 0.1 N NaOH         | Slightly Soluble|
| 6      | Phosphate buffer 7.2 | Soluble       |
Determination of $\lambda_{\text{max}}$ of Drug

![Scan Spectrum Curve](image)

Figure 2: Selection of $\lambda_{\text{max}}$ of Midodrine hydrochloride

| Table 3: Linearity of Midodrine hydrochloride |
|---------------------------------------------|
| Conc. (µg/mL) | 0 | 5 | 10 | 15 | 20 | 25 |
|---------------|---|---|----|----|----|----|
| Rep.1         | 0 | 9.14 | 18.45 | 22.4 | 29.07 | 37.8 |
| Rep.2         | 0 | 9.15 | 18.43 | 22.41 | 29.05 | 37.7 |
| Rep.3         | 0 | 9.18 | 18.42 | 22.39 | 29.06 | 38.05 |
| Mean          | 0 | 9.15667 | 18.4333 | 22.4 | 29.06 | 37.85 |
| S.D.          | 0 | 0.02082 | 0.01528 | 0.01 | 0.01 | 0.18028 |
| R.S.D%        | 0 | 0.22734 | 0.08287 | 0.04464 | 0.03441 | 0.47629 |

Preparation of the calibration curves of the drug using AUC method

![3D spectra of $\lambda_{\text{max}}$ of Midodrine hydrochloride](image)

Figure 3: 3D spectra of $\lambda_{\text{max}}$ of Midodrine hydrochloride

| Table 4: Result of Optical Parameter of Midodrine hydrochloride |
|---------------------------------------------|
| S. No. | Parameters | Observation |
|-------|------------|-------------|
| 1. | $\lambda_{\text{max}}$ | 272.0 nm |
| 2. | Beer’s law limit (µg/mL) | 5-25 |
| 3. | Regression equation | $Y=1.457x+0.852$ |
| 4. | Correlation Coefficient ($r^2$) | 0.996 |

Regression Equation

$Y= mx + c,$

Slope: $M= 1.457$

intercept: $- C= 0.852$

$r^2= 0.996$

![Calibration curve of standard midodrine hydrochloride](image)

Figure 4: Calibration curve of standard Midodrine hydrochloride

![Scan Spectrum Curve](image)

Figure 5: Linearity of standard Midodrine hydrochloride

AUC method

©SRDE Group, All Rights Reserved.
Results of Validation Parameters

Table 5: Assay of Tablet Formulation

| Brand Name | MIDODRINE HYDROCHLORIDE |
|------------|-------------------------|
| Label Claim | % Found | % Purity |
| Proamatine  | 5mg     | 4.98mg   | 99.60    |

Results of Accuracy

Table 6: Recovery Studies for Accuracy of Tablet formulation

| Level of Recovery (%) | 80 | 100 | 120 |
|-----------------------|----|-----|-----|
| Amount Present        | 10 | 10  | 10  |
| Amount of Std. Added  | 8  | 8   | 8   |
| Amount Recovered      | 7.99 | 10.01 | 11.98 |
| % Recovery            | 99.875 | 100.1 | 99.833 |

Table 7: Statistical Validation of Recovery Studies

| Level of Recovery (%) | Drug                  | % Recovery | StandardDeviation* | % RSD  |
|-----------------------|-----------------------|------------|--------------------|--------|
| 80                    | Midodrine hydrochloride | 100.08     | 0.191              | 0.191  |
| 100                   | Midodrine hydrochloride | 100.33     | 0.308              | 0.207  |
| 120                   | Midodrine hydrochloride | 99.94      | 0.127              | 0.127  |

*Denotes average of three determinations

Result of Precision

(A) Repeatability

Table 8: Results of analysis Data of Tablet Formulation

| Drug                  | Label claim | Amount found* | Label claim(%) | S.D. | % RSD |
|-----------------------|-------------|---------------|----------------|------|-------|
| Midodrinehydrochloride | 5 mg        | 4.98          | 99.60          | 0.215| 0.245 |
(B) Intermediate Precision (Inter-day and Intra-day precision)

Table 9: Intra-day and Inter-day precision

|                  | Intra-day Precision | Inter-day Precision |
|------------------|---------------------|---------------------|
|                  | % Label Claim       |                     |
| After 1hr        | 99.98               | First day           |
| After 2hr        | 99.85               | Second day          |
| After 3hr        | 99.52               | Third day           |
| Mean             | 99.783              | Mean                |
| SD               | 0.237               | SD                  |
| % RSD            | 0.238               | % RSD               |

(C) Analyst to Analyst

Table 10: Result of Analyst to Analyst Precision

| Analyst | Label claim (mg) | Amount found* (mg) | Label claim (%) | S.D. | % RSD |
|---------|------------------|--------------------|-----------------|------|-------|
| 1.      | 5                | 4.99               | 99.80           | 0.125| 0.126 |
| 2.      | 5                | 4.98               | 99.60           | 0.105| 0.145 |

Results of LOD and LOQ

Table 11: Results of LOD and LOQ

| S.NO. | Parameter | Results              |
|-------|-----------|----------------------|
| 1.    | LOD       | 0.120µg/ml           |
| 2.    | LOQ       | 0.360µg/ml           |

Results of HPLC method

Mobile Phase Selection

Table 12: Mobile Phase selection

| Mobile phase                                      | Ratio(v/v) | Flow rate | Conclusion                |
|---------------------------------------------------|------------|-----------|----------------------------|
| Water: Methanol                                   | 50:50      | 1.0ml/min | Poor resolution            |
| Methanol: Acetonitrile                            | 50:50      | 1.0ml/min | Peak Broadening            |
| Water (pH adjust 3.5 with TEA): Acetonitrile in   | 20:80      | 1.0ml/min | Good resolution            |
| the ratio of (20:80v/v)                           |            |           |                            |

Taking into consideration the system suitability parameter like RT, Tailing factor, No. of theoretical plates and HETP, the mobile phase found to be most suitable for analysis was Water (pH adjust 3.5 with TEA): Acetonitrile in the ratio of (20:80v/v) in the ratio of 20:80.

The mobile phase was filtered through 0.45µ filter paper to remove particulate matter and then degassed by sonication. Flow rate employed for analysis was 1.0 ml/min

Selection of Separation Variable

Table 13: Selection of Separation Variable

| Variable Column | Condition          |
|-----------------|--------------------|
| Dimension.      | 250mm x 4.60mm     |
| Particle Size   | 5µ                 |
| Bonded Phase    | Octadecysilane (C18) |
| Mobile Phase    | 20                 |
| Water (pH-3 with TEA) | 80               |
Flow rate 1 ml/min
Temperature Room temp.
Sample Size 20 μl
Detection wavelength 272.0 nm

Retention time
Midodrine hydrochloride 3.89 ± 0.3 min

System Suitability Parameters:

| System suitability Parameter | RT      | AUC          | Theoretical plates | Tailing factor |
|------------------------------|---------|--------------|--------------------|---------------|
| Rep-1                        | 3.89    | 1825.658     | 2565              | 1.05          |
| Rep-2                        | 3.85    | 1830.458     | 2570              | 1.03          |
| Rep-3                        | 3.90    | 1840.256     | 2565              | 1.02          |
| Mean                         | 3.86    | 1832.124     | 2566.667          | 1.033         |
| S.D.                         | 0.05    | 7.440        | 2.887             | 0.015         |

Linearity and Calibration Graph

| Std. Conc. µg/ml | 0  | 5  | 10 | 15 | 20 | 25 | 4552.13 | 4540.13 | 4520.26 | 4537.502 |
|------------------|----|----|----|----|----|----|---------|---------|---------|----------|
| 1                | 918.251 | 1825.658 | 2725.658 | 3665.568 | 4552.13 |
| 2                | 915.458 | 1830.458 | 2730.458 | 3680.458 | 4540.13 |
| 3                | 910.457 | 1840.256 | 2740.569 | 3675.587 | 4520.26 |
| Mean             | 914.722 | 1832.124 | 2732.228 | 3673.871 | 4537.502 |
| SD               | 0.000   | 3.949      | 7.440       | 7.612      | 16.096   |
| %RSD             | 0.000   | 0.432      | 0.406       | 0.279      | 0.355    |

Regression Equation

Y = mx + c,
Y = AUC
m = slope = 182.0
X = Conc. in μg/ml
c = Intercept = 5.665
r² = 0.999

Figure 7: Calibration Graph of Midodrine hydrochloride

Figure 8: Chromatogram of Midodrine hydrochloride

Figure 9: Response Ratio Curve of Midodrine hydrochloride
Assay of Tablet Formulation

Table 16: Result of Analysis for Midodrine hydrochloride in Tablet Formulation

| Std Conc. µg/ml | Midodrine Hydrochloride (mg) |
|-----------------|-----------------------------|
| Rep-1           | 4.98                        |
| Rep-2           | 4.99                        |
| Rep-3           | 4.95                        |
| % found* Rep-1  | 99.60                       |
| Rep-2           | 99.80                       |
| Rep-3           | 99.00                       |
| Mean            | 99.467                      |
| SD              | 0.416                       |
| % RSD           | 0.419                       |

*Each reading is mean reading of three batch of formulation

Validation of Developed Method:

Linearity

Table 17: Response Ration Data for Linearity of Midodrine hydrochloride

| Replicates | Concentration (µg/ml) | Mean AUC  | Response Ratio |
|------------|-----------------------|-----------|----------------|
| Rep-1      | 5                     | 914.722   | 182.9444       |
| Rep-2      | 10                    | 1832.124  | 183.2124       |
| Rep-3      | 15                    | 2732.228  | 182.1485       |
| Rep-4      | 20                    | 3673.871  | 183.6936       |
| Rep-5      | 25                    | 4537.502  | 181.5001       |
| Mean       |                       | 182.699   |                |
| S.D.       |                       | 0.873     |                |
| R.S.D.     |                       | 0.478     |                |

Result of Accuracy

Table 18: Recovery Studies of Formulation

| Level of Recovery (%) | 80       | 100      | 120      |
|-----------------------|----------|----------|----------|
|                       | Midodrine hydrochloride | Midodrine hydrochloride | Midodrine hydrochloride |
| Amount present (mg)   | 10       | 10       | 10       |
|                       | 10       | 10       | 10       |
|                       | 10       | 10       | 10       |
| Amount of Std. added (mg) | 8       | 10       | 12       |
|                       | 8        | 10       | 12       |
|                       | 8        | 10       | 12       |
| Amount recovered (mg) | 8.01     | 9.99     | 12.01    |
|                       | 8.02     | 9.98     | 12.01    |
|                       | 7.99     | 9.99     | 12.03    |
| % Recovery            | 100.125  | 99.90    | 100.08   |
|                       | 100.25   | 99.80    | 100.08   |
|                       | 99.875   | 99.90    | 100.25   |
Table 19: Statistical Validation of Recovery Studies

| Level of Recovery (%) | Drug               | % Recovery | Standard Deviation* | % RSD |
|-----------------------|--------------------|------------|---------------------|-------|
| 80                    | Midodrine hydrochloride | 100.083    | 0.191               | 0.191 |
| 100                   | Midodrine hydrochloride | 99.87      | 0.058               | 0.058 |
| 120                   | Midodrine hydrochloride | 100.139    | 0.096               | 0.096 |

*Denotes average of three determinations

Result of precision

(A) Repeatability

Table 20: Results of analysis Data of Tablet Formulation

| Drug                      | Label claim | Amount found* | Label claim (%) | S.D. | % RSD |
|---------------------------|-------------|---------------|-----------------|------|-------|
| Midodrine hydrochloride   | 5 mg        | 4.98 mg       | 99.60           | 0.325| 0.345 |

(B) Intermediate Precision - (Inter-day and Intra-day Precision)

Table 21: Intra-day and Inter-day Precision

| Intra-day Precision | Inter-day Precision |
|---------------------|---------------------|
|                     | % Label Claim       | % Label Claim       |
|                     | Midodrine hydrochloride | Midodrine hydrochloride |
| After 1hr           | 99.89               | First day            | 98.98 |
| After 2hr           | 99.85               | Second day           | 98.01 |
| After 3hr           | 99.54               | Third day            | 97.85 |
| After 4hr           | 99.21               |                      |       |
| After 5hr           | 99.10               |                      |       |
| After 6hr           | 99.05               |                      |       |
| Mean                | 99.440              | Mean                 | 98.98 |
| SD                  | 0.374               | SD                   | 98.01 |
| % RSD               | 0.377               | % RSD                | 97.85 |

(C) Analyst to Analyst

Table 22: Analyst to Analyst

| Analyst | Label claim | Amount found* | Label claim (%) | S.D. | % RSD |
|---------|-------------|---------------|-----------------|------|-------|
| 1       | 5 mg        | 4.95          | 99.00           | 0.165| 0.169 |
| 2       | 5 mg        | 4.96          | 99.20           | 0.185| 0.186 |

Result of Robustness

Table 23: Result of Robustness of Formulation

| Compound                      | % RSD in Normal | Changed Condition n=6 |
|-------------------------------|-----------------|-----------------------|
| Temperature                   | - 5 °C          | + 5 °C                |
| Midodrine hydrochloride       | 0.99            | 1.25                  |
| Flow rate                     | -10%            | 1.12                  |
| Mobile phase ratio            | -2 %            | +2 %                  |
| Midodrine hydrochloride       | 0.68            | 1.05                  |
| Mobile phase ratio            | 0.96            | 1.05                  |
CONCLUSION

This U.V. Spectrophotometric and HPLC method is quite simple, accurate, precise, reproducible, and sensitive. The U.V. and HPLC method has been developed for quantification of Midodrine Hydrochloride in tablet formulation. The method was successfully validated as per ICH guidelines Q2 (R1). The validation procedure confirms that this is an appropriate technique for their quantification in the formulation. It is also used in routine quality control of the formulations containing this entire compound. The accuracy of the method was checked by recovery experiment performed at three different levels i.e., 80%, 100% and 120%. The % recovery was found to be in the range 99.00%–101.00%.

The low values of % RSD are indicative of the accuracy and reproducibility of the method. The precision of the method was studied as an intra-day, inter-day variations and repeatability. The % R.S.D. value less than 2 indicate that the method was precise. Ruggedness of the proposed method was studied with the help of two analysts. The above method was a rapid and cost-effective quality-control tool for routine analysis of drug in bulk and in pharmaceutical dosage form.

REFERENCES

1. Sethi PD, HPLC: Quantitative Analysis of Pharmaceutical Formulation; CBS Publishers and Distributors, New Delhi, 1996, 113-202.
2. Davidson AG, Beckett AH and Stenlake JB, Practical Pharmaceutical Chemistry, 4th edition; CBS Publishers and Distributors, New Delhi, 1989, 276-99.
3. United States Pharmacopoeia-35. National Formulary-30. Vol. 36. Pharmacopoeial forum; 2012. p. 414, 3922.
4. Drug bank. Available from: http://www.drugbank.ca/drugs/DB00211.
5. Ghante MR, Tate AU, Development and validation of UV spectrophotometric methods for estimation of midodrine hydrochloride in bulk and tablet dosage forms, Inveniti Rapid 2015, 3,1-5.
6. Jain PS, Bhadane PV, Chaudhari HP, Surana SJ, Area under curve method development and validation of midodrine hydrochloride, Int J Pharm Chem Anal., 2015,2,154-60.
7. Jain HK, Gujar KN, Randhe VA, Stability indicating RP-HPLC assay method for estimation of midodrine hydrochloride in bulk and tablets. Int J Pharm Pharm Sci., 2016, 8(9), 283-287.
8. Jeffery G.H., Bassett J., Mendham J. and Denrey R.C.; Vogel's Textbook of Quantitative Chemical Analysis; 5th edition; Longman Group UK Ltd, England; 1989; 6-14.
9. Jain N., Jain R., Swami H. and Pandey S.; Indian Journal of Pharmacy and Pharmaceutical sciences, 2009, 1(1), 189-191.
10. Khan, M.R. and Jain, D.; Indian Journal of Pharmaceutical sciences; 2006;64(6);546-548.
11. Meyer Veronica R.; Practical High-Performance Liquid Chromatography; 2nd edition, John wiley and sons, London;1993;56-58.
12. Hemant K. Jain, Kishor N. gujar, Varsha A. Randhe, Stability indicating RP-HPLC assay method for estimation of midodrine hydrochloride in bulk and tablets, International Journal of Pharmacy and Pharmaceutical Sciences, 2016; 8(9): 283-287.
13. S. Gopalakrishnan, K. Jothy and K. Dhanalakshmi, Analytical method development and validation of HPLC method for the determination of omeprazole in capsule dosage form, Elixir Appl. Chem. 52 (2012) 11283-11286.
14. Kalakonda Sri Nataraj, Mohammad BadrudDuza, Kalyani Pragallapati, Dussa Kiran Kumar, Development and validation of RP-HPLC method for the estimation of omeprazole in bulk and capsule dosage forms, International Current Pharmaceutical Journal 2012, 1(11): 366-369.
15. Hemant K. Jain, Kishor N. Gujar and Varsha A. Randhe. First order derivative spectrophotometric method development and validation for midodrine hydrochloride in bulk and tablets. World journal of pharmacy and pharmaceutical sciences. 2016; Vol 5, Issue 7, 1760-67.
16. Singh Sunil, Choudhary Nisha, Rai Jyoti, Inamullah, Sharma Surabhi, Yadav Ajit Kumar, Gautam Hemendra, Chaturvedi Shashank, Agrawal Vipin Kumar, Validated RP-UPLC Method Development for Estimation of Lansoprazole in Tablet Dosage Form, International Journal of Pharmaceutical Sciences and Drug Research 2013; 5(3): 105-107.
17. Yarram Rama Koti Reddy, Sudershana Reddy G, M. R. P. Reddy and K. Mulkanti, Rapid simultaneous determination of aspirin and esomeprozole magnesium in combined tablets by validated ultra-performance liquid chromatographic method, Journal of Chemical and Pharmaceutical Research, 2013, 5(4):181-187.

How to cite this article:
Dhote V, Jain P and Jain V. A new analytical method development and validation for the estimation of Midodrine HCl by UV and HPLC. Int. J. Res. Dev. Pharm. L. Sci. 2018; 7(4): 3060-3070. doi: 10.13040/IJRDP.L.2278-0238.7(4).3060-3070.

This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.